ALBERT LABS INTL. CORP. (F:VB50) — Market Cap & Net Worth
Market Cap & Net Worth: ALBERT LABS INTL. CORP. (VB50)
ALBERT LABS INTL. CORP. (F:VB50) has a market capitalization of $372.07K (€318.25K) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #30933 globally and #2745 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALBERT LABS INTL. CORP.'s stock price €0.01 by its total outstanding shares 74413267 (74.41 Million). Review total liabilities of ALBERT LABS INTL. CORP. to assess the company's total debt and financial obligations.
ALBERT LABS INTL. CORP. Market Cap History: 2022 to 2026
ALBERT LABS INTL. CORP.'s market capitalization history from 2022 to 2026. Data shows change from $2.00 Million to $434.98K (-49.71% CAGR).
ALBERT LABS INTL. CORP. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALBERT LABS INTL. CORP.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of VB50 by Market Capitalization
Companies near ALBERT LABS INTL. CORP. in the global market cap rankings as of June 19, 2026.
Key companies related to ALBERT LABS INTL. CORP. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
ALBERT LABS INTL. CORP. Historical Marketcap From 2022 to 2026
Between 2022 and today, ALBERT LABS INTL. CORP.'s market cap moved from $2.00 Million to $ 434.98K, with a yearly change of -49.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €434.98K | 0.00% |
| 2025 | €434.98K | 0.00% |
| 2024 | €434.98K | +25.00% |
| 2023 | €347.99K | -82.61% |
| 2022 | €2.00 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of ALBERT LABS INTL. CORP. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $372.07K USD |
| MoneyControl | $372.07K USD |
| MarketWatch | $372.07K USD |
| marketcap.company | $372.07K USD |
| Reuters | $372.07K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ALBERT LABS INTL. CORP.
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.